The overall increase in the potential risk of uterine cancer with tamoxifen use is low (under 1%), and it goes back to normal inside of a number of years of stopping the drug. Development taking place six or more months after initiating the 1st endocrine therapy for metastatic illness (possibly https://henryn419bgk1.wikissl.com/user